glp 1 agonist risks GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists GLP-1 Agonists For Obesity In

Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study

Sergey Terushkin, MD, FACS Key Takeaways For decades, the field of bariatric medicine had two distinct lanes: lifestyle changes (which rarely produce massive, sustained weight loss for the morbidly obese) and bariatric surgery (which is highly effective but invasive)

Although widespread adoption of GLP-1 and GLP-1/GIP medications has the potential to improve population health by reducing obesity-related diseases, the financial implications are considerable

In addition, prevention and treatment of hypoglycemia with excessive carbohydrates also contribute to weight gain

GLP-1 alternatives for weight loss GLP-1 agonists have surged in popularity over the last few years, but theyre not the only weight loss medications available